In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

Genetic, biochemical and structural studies have implicated Argonaute proteins as the catalytic core of the RNAi effector complex, RISC. Here we show that recombinant, human Argonaute2 can combine ...

Vial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE and its gene product, Activin E -- Leading key opinion leaders (KOL ...

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...

AstraZeneca is set to pay Silence Therapeutics $60 million (€55 million) to work on siRNA therapies against cardiovascular, renal, metabolic and respiratory disease targets. The upfront cash fee is ...

RNA interference silences gene expression through short interfering 21–23-mer double-strand RNA segments that guide mRNA degradation in a sequence-specific fashion. Here we report that siRNAs inhibit ...

In a study published in Cell Reports Physical Science on Nov. 25, a research team reported the development of an innovative intelligent light-guided biohybrid system, the CTPA/siCSF1R system, to ...

GSK has signed a licensing deal with Empirico for its respiratory disease-focused silent interfering RNA (siRNA), EMP-012. The UK-based big pharma purchased the oligonucleotide, which is currently in ...

Transfecting siRNA with a high efficiency won’t be a challenge for you anymore thanks to these tips. siRNA transfection is a powerful tool to understand underlying mechanisms in gene regulation and ...

Inherited genetic variation in EPHA5, FGD4, and NRDG1 and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101. Background: ...